Randomized Controlled Trial to Evaluate Transdermal Testosterone in Female Cancer Survivors With Decreased Libido; North Central Cancer Treatment Group Protocol N02C3
| Autor: | Wanda L. DeKrey, Pamela J. Atherton, Charles L. Loprinzi, Donald B. Wender, Tim Larson, Paul C. Carpenter, Jeff A. Sloan, Debra L. Barton, Robert J. Dalton, James D. Bearden, Ernie P. Balcueva, Albert M. Bernath |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty medicine.drug_class Libido Sexual Behavior Administration Cutaneous Placebo Interviews as Topic Placebos Neoplasms Surveys and Questionnaires Internal medicine medicine Humans Testosterone Survivors Aged Gynecology business.industry Testosterone (patch) Middle Aged Decreased Libido Sexual desire Treatment Outcome Sexual dysfunction Oncology Estrogen Female medicine.symptom Sexual function business |
| Zdroj: | JNCI Journal of the National Cancer Institute. 99:672-679 |
| ISSN: | 1460-2105 0027-8874 |
| DOI: | 10.1093/jnci/djk149 |
| Popis: | BACKGROUND Decreased libido is one of several changes in sexual function that are often experienced by female cancer patients. Transdermal testosterone therapy has been associated with increased libido among estrogen-replete women who report low libido. METHODS In a phase III randomized, placebo-controlled crossover clinical trial, we evaluated whether transdermal testosterone would increase sexual desire in female cancer survivors. Postmenopausal women with a history of cancer and no current evidence of disease were eligible if they reported a decrease in sexual desire and had a sexual partner. Eligible women were randomly assigned to receive 2% testosterone in Vanicream for a testosterone dose of 10 mg daily or placebo Vanicream for 4 weeks and were then crossed over to the opposite treatment for an additional 4 weeks. The primary endpoint was sexual desire or libido, as measured using the desire subscales of the Changes in Sexual Functioning Questionnaire, as assessed at baseline and at the end of 4 and 8 weeks of treatment. Serum levels of bioavailable testosterone were measured at the same times. All statistical tests were two-sided. RESULTS We enrolled 150 women. Women who were on active testosterone cream had higher serum levels of bioavailable testosterone than women on placebo (mean change from baseline, testosterone versus placebo, week 4, 11.57% versus 0%, difference = 11.57%, 95% confidence interval [CI] = 8.49% to 14.65%; week 8, 10.21% versus 0.28%, difference = 9.92%, 95% CI = 5.42% to 14.42%; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|